Facebook Linkedin RSS Twitter Youtube
Home 2012

Bacterial pneumonia

Forest Coughs Up $25M for Nabriva’s Phase II Antibacterial, Right to Take Over Company
Infectious Diseases

Forest Coughs Up $25M for Nabriva’s Phase II Antibacterial, Right to Take Over Company

Cepheid Gets $1.3M to Develop Sample Prep Methods for Detecting Bloodstream Bacteria
Infectious Diseases

Cepheid Gets $1.3M to Develop Sample Prep Methods for Detecting Bloodstream Bacteria

EC Grants CE Mark for Trinity’s Point-of-Care Test for Giardiasis
Infectious Diseases

EC Grants CE Mark for Trinity’s Point-of-Care Test for Giardiasis

GSK Awarded $38.5M Contract to Develop Antibiotic for Biodefense and Drug-Resistant Infections
Drug Discovery

GSK Awarded $38.5M Contract to Develop Antibiotic for Biodefense and Drug-Resistant Infections

Bayer Pays Trius $25M Up Front for License to Phase III-Stage Antibiotic
Drug Discovery

Bayer Pays Trius $25M Up Front for License to Phase III-Stage Antibiotic

Curetis Obtains €24.5M to Support Commercialization of Diagnostics for Infectious Diseases
Drug Discovery

Curetis Obtains €24.5M to Support Commercialization of Diagnostics for Infectious Diseases

New Macrolides Essential to Treat CABP
Drug Discovery

New Macrolides Essential to Treat CABP

Nabriva Therapeutics Raises About $22M to Advance Drug-Resistant Antibiotic Pipeline
Drug Discovery

Nabriva Therapeutics Raises About $22M to Advance Drug-Resistant Antibiotic Pipeline

Genocea Closes $23M Series A Financing Round
Industry News

Genocea Closes $23M Series A Financing Round

FDA Asks for More Information Before Sanctioning J&JPRD’s Drug for Hospital-Acquired Pneumonia
News

FDA Asks for More Information Before Sanctioning J&JPRD’s Drug for Hospital-Acquired Pneumonia

1234Page 3 of 4
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.